Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 15/20 | 0.47 |
| ▸ | GABRB3 | P28472 | 15/20 | 0.47 |
| ▸ | GABRA5 | P31644 | 15/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.39 |
| ▸ | CDK9 | P50750 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4242652 | 0.86 | LMNA (0.53) | GABRG2GABRB3GABRA5FGFR1 | |
| SCHEMBL31509276 | 0.84 | GRIN2B (0.42) | GABRG2GABRB3GABRA5FGFR1CDK9 | |
| SCHEMBL4243941 | 0.82 | LMNA (0.59) | FGFR1CDK9 | |
| SCHEMBL5695756 | 0.79 | HDAC1 (0.48) | FGFR1 | |
| SCHEMBL17678092 | 0.78 | GABRG2 (0.50) | GABRG2GABRB3GABRA5CDK9 | |
| SCHEMBL17678028 | 0.78 | GABRG2 (0.50) | GABRG2GABRB3GABRA5 | |
| SCHEMBL13931440 | 0.77 | HDAC1 (0.50) | FGFR1 | |
| SCHEMBL21026237 | 0.75 | GABRG2 (0.48) | GABRG2GABRB3GABRA5 | |
| SCHEMBL28684427 | 0.75 | POLB (0.55) | FGFR1 | |
| SCHEMBL3414135 | 0.75 | HDAC1 (0.53) | FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048252-A1 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-02-19 | — | — | US | disclosed |
| EP-1993536-A2 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SmithKline Beecham Corporation (US) | 2008-11-26 | — | — | EP | disclosed |
| US-20070249599-A1 | Novel Chemical Compounds | DUFFY KEVIN J | 2007-10-25 | — | — | US | disclosed |
| WO-2007103755-A2 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249599-A1 | Novel Chemical Compounds | HIPK3, HIPK1, HIPK4 | GABRG2 4780/4885GABRB3 4016/4885GABRA5 4700/4885 |
| US-20090048252-A1 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | PIK3CA, BTK, PI4KA | GABRG2 3604/4885GABRB3 3083/4885GABRA5 3093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.